BACKGROUND: Previous studies have shown increased familial risk for chronic lymphocytic leukemia. In the most comprehensive study to date, we evaluated risk of chronic lymphocytic leukemia and lymphoproliferative disorders among first-degree relatives of chronic lymphocytic leukemia cases compared to first-degree relatives of controls. DESIGN AND METHODS: Population-based registry data from Sweden were used to evaluate outcomes in 26,947 first-degree relatives of 9,717 chronic lymphocytic leukemia patients (diagnosed 1958-2004) compared with 107,223 first-degree relatives of 38,159 matched controls. Using a marginal survival model, we calculated relative risks (RR) and 95% confidence intervals as measures of familial aggregation. RESULTS: Compared to relatives of controls, relatives of chronic lymphocytic leukemia patients had an increased risk for chronic lymphocytic leukemia (RR=8.5, 6.1-11.7) and other non-Hodgkin's lymphomas (NHLs) (RR=1.9, 1.5-2.3). Evaluating NHL subtypes, we found a striking excess of indolent B-cell NHL, specifically lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and hairy cell leukemia. No excesses of aggressive B-cell or T-cell lymphomas were found. There was no statistical excess of Hodgkin's lymphoma, multiple myeloma, or the precursor condition, monoclonal gammopathy of undetermined significance, among chronic lymphocytic leukemia relatives. CONCLUSIONS: These familial aggregations are striking and provide novel clues to research designed to uncover early pathogenetic mechanisms in chronic lymphocytic leukemia including studies to identify germ line susceptibility genes. However, clinicians should counsel their chronic lymphocytic leukemia patients emphasizing that because the baseline population risks are low, the absolute risk for a first-degree relative to develop chronic lymphocytic leukemia or another indolent lymphoma is low. At this time, an increased medical surveillance of first-degree relatives of chronic lymphocytic leukemia patients has no role outside research studies.
BACKGROUND: Previous studies have shown increased familial risk for chronic lymphocytic leukemia. In the most comprehensive study to date, we evaluated risk of chronic lymphocytic leukemia and lymphoproliferative disorders among first-degree relatives of chronic lymphocytic leukemia cases compared to first-degree relatives of controls. DESIGN AND METHODS: Population-based registry data from Sweden were used to evaluate outcomes in 26,947 first-degree relatives of 9,717 chronic lymphocytic leukemiapatients (diagnosed 1958-2004) compared with 107,223 first-degree relatives of 38,159 matched controls. Using a marginal survival model, we calculated relative risks (RR) and 95% confidence intervals as measures of familial aggregation. RESULTS: Compared to relatives of controls, relatives of chronic lymphocytic leukemiapatients had an increased risk for chronic lymphocytic leukemia (RR=8.5, 6.1-11.7) and other non-Hodgkin's lymphomas (NHLs) (RR=1.9, 1.5-2.3). Evaluating NHL subtypes, we found a striking excess of indolent B-cell NHL, specifically lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and hairy cell leukemia. No excesses of aggressive B-cell or T-cell lymphomas were found. There was no statistical excess of Hodgkin's lymphoma, multiple myeloma, or the precursor condition, monoclonal gammopathy of undetermined significance, among chronic lymphocytic leukemia relatives. CONCLUSIONS: These familial aggregations are striking and provide novel clues to research designed to uncover early pathogenetic mechanisms in chronic lymphocytic leukemia including studies to identify germ line susceptibility genes. However, clinicians should counsel their chronic lymphocytic leukemiapatients emphasizing that because the baseline population risks are low, the absolute risk for a first-degree relative to develop chronic lymphocytic leukemia or another indolent lymphoma is low. At this time, an increased medical surveillance of first-degree relatives of chronic lymphocytic leukemiapatients has no role outside research studies.
Authors: Maria Chiara Di Bernardo; Dalemari Crowther-Swanepoel; Peter Broderick; Emily Webb; Gabrielle Sellick; Ruth Wild; Kate Sullivan; Jayaram Vijayakrishnan; Yufei Wang; Alan M Pittman; Nicola J Sunter; Andrew G Hall; Martin J S Dyer; Estella Matutes; Claire Dearden; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; Peter Hillmen; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; James M Allan; Daniel Catovsky; Richard S Houlston Journal: Nat Genet Date: 2008-08-31 Impact factor: 38.330
Authors: Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm Journal: Blood Date: 2008-05-01 Impact factor: 22.113
Authors: Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Mary L McMaster; Ingemar Turesson; Ola Landgren Journal: Blood Date: 2008-08-13 Impact factor: 22.113
Authors: Nancy M Hardy; Christine Grady; Rebecca Pentz; Maryalice Stetler-Stevenson; Mark Raffeld; Laura S Fontaine; Rebecca Babb; Michael R Bishop; Neil Caporaso; Gerald E Marti Journal: Br J Haematol Date: 2007-12 Impact factor: 6.998
Authors: Martha S Linet; Mary K Schubauer-Berigan; Dennis D Weisenburger; David B Richardson; Ola Landgren; Aaron Blair; Sharon Silver; R William Field; Glyn Caldwell; Maureen Hatch; Graça M Dores Journal: Br J Haematol Date: 2007-12 Impact factor: 6.998
Authors: Andy C Rawstron; Fiona L Bennett; Sheila J M O'Connor; Marwan Kwok; James A L Fenton; Marieth Plummer; Ruth de Tute; Roger G Owen; Stephen J Richards; Andrew S Jack; Peter Hillmen Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Tait D Shanafelt; Neil E Kay; Greg Jenkins; Timothy G Call; Clive S Zent; Diane F Jelinek; William G Morice; Justin Boysen; Liam Zakko; Susan Schwager; Susan L Slager; Curtis A Hanson Journal: Blood Date: 2008-11-17 Impact factor: 22.113
Authors: Lynn R Goldin; Mark C Lanasa; Susan L Slager; James R Cerhan; Celine M Vachon; Sara S Strom; Nicola J Camp; Logan G Spector; Jose F Leis; Vicki A Morrison; Martha Glenn; Kari G Rabe; Sara J Achenbach; Sallie D Algood; Fatima Abbasi; Laura Fontaine; Michelle Yau; Laura Z Rassenti; Neil E Kay; Timothy G Call; Curtis A Hanson; J Brice Weinberg; Gerald E Marti; Neil E Caporaso Journal: Br J Haematol Date: 2010-08-25 Impact factor: 6.998
Authors: Brian A McCarthy; Sophia Yancopoulos; Mike Tipping; Xiao-Jie Yan; Xue Ping Wang; Fiona Bennett; Wentian Li; Martin Lesser; Santanu Paul; Erin Boyle; Carolina Moreno; Rosa Catera; Bradley T Messmer; Giovanna Cutrona; Manlio Ferrarini; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Andrew C Rawstron; Nicholas Chiorazzi Journal: Immunol Res Date: 2015-12 Impact factor: 2.829
Authors: Susan L Slager; Lynn R Goldin; Sara S Strom; Mark C Lanasa; Logan G Spector; Laura Rassenti; Jose F Leis; Nicola J Camp; Neil E Kay; Celine M Vachon; Martha Glenn; J Brice Weinberg; Kari G Rabe; Julie M Cunningham; Sara J Achenbach; Curtis A Hanson; Gerald E Marti; Timothy G Call; Neil E Caporaso; James R Cerhan Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Ola Landgren; Maher Albitar; Wanlong Ma; Fatima Abbasi; Richard B Hayes; Paolo Ghia; Gerald E Marti; Neil E Caporaso Journal: N Engl J Med Date: 2009-02-12 Impact factor: 91.245
Authors: Helen E Speedy; Maria Chiara Di Bernardo; Georgina P Sava; Martin J S Dyer; Amy Holroyd; Yufei Wang; Nicola J Sunter; Larry Mansouri; Gunnar Juliusson; Karin E Smedby; Göran Roos; Sandrine Jayne; Aneela Majid; Claire Dearden; Andrew G Hall; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; Richard Rosenquist; Daniel Catovsky; James M Allan; Richard S Houlston Journal: Nat Genet Date: 2013-12-01 Impact factor: 38.330